Lpath and Echelon Introduce New Cancer Research Assay Based on Lpath's Breakthrough Anti-Cancer Drug Candidate, Sphingomab(TM)

SAN DIEGO, July 10 /PRNewswire/ --

Lpath, Inc. (OTC: LPTN), the category leader in therapeutic agents
against bioactive lipids, and Echelon Biosciences Inc., a unit of AEterna
Zentaris (Nasdaq: AEZS, TSX: AEZ) and a pioneer in the field of lipid
research and lipid-protein interactions, have introduced a new assay for
cancer research based on Lpath's patented breakthrough anti-cancer drug
candidate, Sphingomab(TM). The assay is offered exclusively via Echelon's
order line at +1-866-588-0455 and Echelon catalog number K-1900.

Sphingomab is a monoclonal antibody against sphingosine-1-phosphate
(S1P), an important bioactive lipid that has been well validated as a cancer
drug target. Recent scientific literature suggests S1P is a potent
tumorigenic growth factor that is likely released from tumor cells, and S1P
may be a novel biomarker for early-stage cancer detection. S1P, a key
component of the sphingolipid signaling cascade, initiates a proliferative,
pro-angiogenic, and anti-apoptotic sequence of events contributing to cancer
progression. Sphingosine kinase, the enzyme that produces S1P, has also been
shown to be up-regulated in a variety of cancer types.

The new assay, co-developed by Lpath and Echelon, is designed as a
sensitive and robust method for the quantification of S1P. It was developed
under an exclusive agreement that grants Echelon world-wide rights to
develop, market, and sell a "research use only" assay kit that incorporates
Sphingomab as a method to determine the concentration of S1P.

"The introduction of this assay represents a major milestone for Lath and
the advancement of Sphingomab," notes Dr. Roger Sabbadini, Lpath's founder
and chief scientific officer. "It provides the scientific research community
a powerful new vehicle to further understand the role of S1P and validate it
as a promising therapeutic target for the treatment of cancer and a variety
of other indications. Echelon is a well regarded and highly capable company
in the area of phospholipid and sphingolipid research products, and has
proven to be an ideal partner in this endeavor."

W. Tim Miller, Echelon's president and CEO, added, "We look forward to
further collaborating with Lpath and applying its advanced technology to
develop an entire suite of sphingosine-related reagents and assays for
advancing the research of cancer and human cellular disease."

Independent research demonstrating the profound anti-cancer effects of
Sphingomab were published in the March 2006 edition of the prestigious
journal, Cancer Cell.

(See:
http://www.cancercell.org/content/article/fulltext?uid=PIIS1535610806000602).

About Lpath

Lpath, Inc., headquartered in San Diego, California, is the category
leader in lipidomic-based therapeutics, an emerging field of medical science
whereby bioactive signaling lipids are targeted for treating important human
diseases. Lpath's lead product candidate, Sphingomab, is a monoclonal
antibody against a validated cancer target, sphingosine-1-phosphate (S1P),
and has demonstrated compelling results in preclinical studies against
multiple forms of cancers, against AMD, and against heart failure. Sphingomab
is potently anti-angiogenic, yet it has other mechanisms of action that may
prove advantageous in the clinical setting. As such, Lpath believes
Sphingomab may represent the next generation of anti-angiogenesis-based
therapeutics.

Lpath's second product candidate, Lpathomab(TM), is a monoclonal antibody
against lysophosphatidic acid (LPA), a key bioactive lipid that has been long
recognized as a significant promoter of cancer-cell growth and metastasis in
a broad range of tumor types.

Lpath's unique ability to generate antibodies against bioactive lipids is
based on its patented ImmuneY2(TM) technology. The company intends to apply
the ImmuneY2 process to other important lipid-signaling agents, thereby
providing a robust pipeline of antibody-based drug candidates.

Sphingomab is a trademark of Lpath Inc. For more information about Lpath
and Sphingomab visit http://www.lpath.com.

About Echelon

Echelon Biosciences Inc. is a leader in the field of lipid research and
lipid-protein interactions that are essential top-level regulators in
numerous cell signaling cascades. Abnormal signaling elements lead to many
diseases like cancer, inflammation, diabetes, and cardiovascular disease.
Echelon has been a top supplier of research information, lipid signaling
assay and reagent technology for years with 600 customers in 40 countries
around the world including major pharmaceutical companies and leading
academic research institutions. It's rapidly expanding family of novel
research assays and reagents for phospholipids, sphingolipids, and
lysophospholipids provide the most advanced offering of its kind. Echelon
also has an early-stage program in anti-infective development, targeting a
novel pathway found in many problematic Gram negative bacteria. Echelon is a
wholly owned subsidiary of Aeterna Zentaris, Inc. For more information about
Echelon, visit http://www.echelon-inc.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. For example, there can be no assurance that required clinical
trials will be successful, necessary regulatory approvals will be obtained,
or the proposed treatments will prove to be safe or effective. Actual results
may also differ substantially from those described in or contemplated by this
press release due to risks and uncertainties that exist in our operations and
business environment, including, without limitation, our limited experience
in the development of therapeutic drugs, our dependence upon proprietary
technology, our history of operating losses and accumulated deficits, our
reliance on research grants, current and future competition, and other risks
described from time to time in our filings with the Securities and Exchange
Commission. We undertake no obligation to release publicly the results of any
revisions to these forward-looking statements to reflect events or
circumstances arising after the date hereof.

Lpath Contacts:
    Scott Pancoast,
    President and CEO
    spancoast@lpath.com

    Lpath Investor Relations
    Liolios Group, Inc.
    Scott Liolios or Ron Both
    info@liolios.com
    +1-949-574-3860

    Echelon Contacts:
    W. Tim Miller
    President and CEO
    wtmiller@echelon-inc.com
    +1-801-588-0455

    Web site: http://www.lpath.com
              http://www.echelon-inc.com